Confusion of therapeutic approaches: In reply;Vermengung von therapieformen: Schlusswort

Deutsches Arzteblatt International

Volumn 111, Issue 22, 2014, Pages 405-406

  Schlitt, Axel ^a  

^a Paracelsus Harz Clinic Bad Suderode   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEART FAILURE; LETTER; THERAPY; CHEMICALLY INDUCED; HEART DISEASE; HUMAN; MORTALITY; NEOPLASMS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; NEOPLASMS;

EID: 84904248519     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0405b     Document Type: Letter

References (4)

1. Schmiedinger M, Zielinski CC, Vogl UM, et al.: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204-12.
2. Chintalgattu V, Patel SS, Khakoo AY: Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23: 97-107.
3. Yancy CW, Jessup M, Bozkurt B, et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239.
4. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C: Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 2014; 111: 161-8.